Mitofusin activators and methods of use thereof
US-2024082180-A1 · Mar 14, 2024 · US
Compositions and methods of Rit1 inhibition
US10525040B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10525040-B2 |
| Application number | US-201615738353-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 29, 2016 |
| Priority date | Jun 29, 2015 |
| Publication date | Jan 7, 2020 |
| Grant date | Jan 7, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.
First claim
Opening claim text (preview).
What is claimed is: 1. A pharmaceutical composition, comprising a compound having a structure according to Formula Ia and a pharmaceutically acceptable carrier; wherein R 1 , R 2 , and R 4 are independently aryl, heteroaryl, heterocycle, or fused heterocycle, each optionally substituted; and wherein R 3 and R 5 are independently hydrogen or lower alkyl. 2. The pharmaceutical composition of claim 1 wherein R 3 and R 5 are hydrogen. 3. The pharmaceutical composition of claim 1 wherein at least one of R 1 and R 2 is phenyl. 4. The pharmaceutical composition of claim 1 wherein R 4 is a 5- or 6-membered heterocyclic ring. 5. The pharmaceutical composition of claim 1 wherein R 4 is a triazole, an imidazole, or a pyridine.
Assignees
Inventors
Classifications
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Antineoplastic agents · CPC title
ortho- or peri-condensed with carbocyclic ring systems · CPC title
- A61K31/4196Primary
1,2,4-Triazoles · CPC title
containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole (nicotine A61K31/465) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10525040B2 cover?
- Various compounds, compositions, and methods for inhibition of Rit1 are presented. In especially preferred aspects, contemplated compounds and compositions are suitable for treatment of cancers and other diseases associated with Rit1 signaling.
- Who is the assignee on this patent?
- Nantbio Inc, Nantomics Llc, Nant Holdings Ip Llc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4196. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 07 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).